Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 13 Jan 2026, 03:28 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The video discusses the potential for Novo Nordisk (NVO) and Eli Lilly (LLY) stocks to continue their upward trend. For NVO, the analysis suggests that despite recent gains, the stock is still undervalued compared to its intrinsic value of $85.38, with a current market price of $56.26. The stock recently recovered from a weekly low of $43. For LLY, it is presented as a 'strong buy' and a potential '2025 top performer', with an expectation of continued strong performance. Both companies are in the weight loss drug market, with the introduction of oral versions of their treatments, increasing accessibility and potentially driving future growth.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
